Expert Consensus on Betahistine Mesylate in the Treatment of Vertigo

doi:10.12114/j.issn.1007-9572.2023.0312

Abstract

Abstract:

In order to standardize scientific drug use in vertigo, the Vertigo Committee of the Chinese Medical Education Association established an expert group to form Expert Consensus on Betahistine Mesylate in the Treatment of Vertigo after repeated discussion based on the existing medical evidence, and combined with the rich clinical experience of experts. The consensus includes the pharmacological basis of histamines, the strength of recommendation, dosage, course, review methods, medication for special populations, adverse drug reactions and other aspects of betahistine mesylate in common vertigo diseases (such as benign paroxysmal position vertigo, Menieres disease, and vestibular neuritis, etc.) to guide doctors in clinical work.

Key words: Vertigo, Benign paroxysmal positional vertigo, Meniere disease, Vestibular neuronitis, Betahistine, Clinical medication

摘要：

为规范眩晕症的科学用药，中国医药教育协会眩晕专业委员会特成立专家小组，在纳入现有医学科学证据的基础上，结合专家丰富的临床经验，经反复讨论后形成《甲磺酸倍他司汀治疗眩晕症的专家共识》。本共识包括组胺类药物的药理基础以及甲磺酸倍他司汀在常见眩晕疾病（如良性阵发性位置性眩晕、梅尼埃病、前庭神经炎等）中的用药推荐等级、剂量、疗程、复查方法、特殊人群用药、药物不良反应等方面，旨在帮助医生提升临床实践水平。

关键词: 眩晕, 良性阵发性位置性眩晕, 梅尼埃病, 前庭神经元炎, 倍他司汀, 临床用药

The Vertigo Committee of the Chinese Medical Education Association. Expert Consensus on Betahistine Mesylate in the Treatment of Vertigo[J]. Chinese General Practice, 2023, 26(29): 3591-3598. DOI: 10.12114/j.issn.1007-9572.2023.0312.
中国医药教育协会眩晕专业委员会. 甲磺酸倍他司汀治疗眩晕症的专家共识[J]. 中国全科医学, 2023, 26(29): 3591-3598. DOI: 10.12114/j.issn.1007-9572.2023.0312.

Figures/Tables 6

References 73

[1]	LACOUR M, STERKERS O. Histamine and betahistine in the treatment of vertigo：elucidation of mechanisms of action[J]. CNS Drugs，2001,15(11):853-870. DOI：10.2165/00023210-200115110-00004.
[2]	CHENG L, LIU J Y, CHEN Z. The histaminergic system in neuropsychiatric disorders[J]. Biomolecules，2021,11(9):1345. DOI：10.3390/biom11091345.
[3]	PANULA P, NUUTINEN S. The histaminergic network in the brain：basic organization and role in disease[J]. Nat Rev Neurosci，2013,14(7):472-487. DOI：10.1038/nrn3526.
[4]	HAAS H L, SERGEEVA O A, SELBACH O. Histamine in the nervous system[J]. Physiol Rev，2008,88(3):1183-1241. DOI：10.1152/physrev.00043.2007.
[5]	ZAMERGRAD M V, KUNELSKAYA N L, GUSEVA A L, et al. Betahistine in vestibular disorders：current concepts and perspectives[J]. Vestn Otorinolaringol，2021,86(2):73-81. DOI：10.17116/otorino20218602173.
[6]	MURDIN L, HUSSAIN K, SCHILDER A G M. Betahistine for symptoms of vertigo[J]. Cochrane Database Syst Rev，2016,2016(6):CD010696. DOI：10.1002/14651858.CD010696.pub2.
[7]	BROWN R E, STEVENS D R, HAAS H L. The physiology of brain histamine[J]. Prog Neurobiol，2001,63(6):637-672. DOI：10.1016/S0301-0082(00)00039-3.
[8]	LACOUR M. Betahistine treatment in managing vertigo and improving vestibular compensation：clarification[J]. J Vestib Res，2013,23(3):139-151. DOI：10.3233/VES-130496.
[9]	BERTLICH M, IHLER F, FREYTAG S, et al. Histaminergic H₃-heteroreceptors as a potential mediator of betahistine-induced increase in cochlear blood flow[J]. Audiol Neurootol，2015,20(5):283-293. DOI：10.1159/000368293.
[10]	DESMADRYL G, GABOYARD-NIAY S, BRUGEAUD A, et al. Histamine H₄ receptor antagonists as potent modulators of mammalian vestibular primary neuron excitability[J]. Br J Pharmacol，2012,167(4):905-916. DOI：10.1111/j.1476-5381.2012.02049.x.
[11]	LI B, ZHU J N, WANG J J. Histaminergic afferent system in the cerebellum：structure and function[J]. Cerebellum Ataxias，2014,1:5. DOI：10.1186/2053-8871-1-5.
[12]	BERGQUIST F, RUTHVEN A, LUDWIG M, et al. Histaminergic and glycinergic modulation of GABA release in the vestibular nuclei of normal and labyrinthectomised rats[J]. J Physiol，2006,577(Pt 3):857-868. DOI：10.1113/jphysiol.2006.120493.
[13]	CHEN Z P, ZHANG X Y, PENG S Y, et al. Histamine H1 receptor contributes to vestibular compensation[J]. J Neurosci，2019,39(3):420-433. DOI：10.1523/JNEUROSCI.1350-18.2018.
[14]	LIU J Z, HOU Y J, LIU J B, et al. Comparison of pharmacodynamic property of two kinds of betahistine drugs[J]. Chinese Journal of Structural Chemistry，2018,37(4):564-570. DOI：10.14102/j.cnki.0254-5861.2011-1861.
[15]	LI S F, WONG S, SETHIA S, et al. Investigation of solubility and dissolution of a free base and two different salt forms as a function of pH[J]. Pharm Res，2005,22(4):628-635. DOI：10.1007/s11095-005-2504-z.
[16]	CHEN X Y, ZHONG D F, DUAN J L, et al. LC-MS-MS analysis of 2-pyridylacetic acid，a major metabolite of betahistine：application to a pharmacokinetic study in healthy volunteers[J]. Xenobiotica，2003,33(12):1261-1271. DOI：10.1080/716689336.
[17]	AL-TAMIMI D J, AMMOO A M, ALANI M E, et al. Pharmacokinetics and dose proportionality of betahistine in healthy individuals[J]. Sci Pharm，2020,88(1):13. DOI：10.3390/scipharm88010013.
[18]	HAZRA A, MAROO N. Betahistine dihydrochloride or betahistine mesilate：two sides of the same coin or two different coins[J]. Int J Basic Clin Pharmacol，2017,6(8):1833. DOI：10.18203/2319-2003.ijbcp20173266.
[19]	RAMOS ALCOCER R, LEDEZMA RODRÍGUEZ J G, NAVAS ROMERO A, et al. Use of betahistine in the treatment of peripheral vertigo[J]. Acta Otolaryngol，2015,135(12):1205-1211. DOI：10.3109/00016489.2015.1072873.
[20]	DEVANTIER L, HOUGAARD D, HÄNDEL M N, et al. Using betahistine in the treatment of patients with Menières disease：a meta-analysis with the current randomized-controlled evidence[J]. Acta Otolaryngol，2020,140(10):845-853. DOI：10.1080/00016489.2020.1777326.
[21]	KRUSCHINSKI C, KERSTING M, BREULL A, et al. Frequency of dizziness-related diagnoses and prescriptions in a general practice database[J]. Z Evid Fortbild Qual Gesundhwes，2008,102(5):313-319. DOI：10.1016/j.zefq.2008.05.001.
[22]	VAN ESCH B, VAN DER ZAAG-LOONEN H, BRUINTJES T, et al. Betahistine in ménières disease or syndrome：a systematic review[J]. Audiol Neurootol，2022,27(1):1-33. DOI：10.1159/000515821.
[23]	GANANÇA M M, CAOVILLA H H, GANANÇA F F. Comparable efficacy and tolerability between twice daily and three times daily betahistine for Ménières disease[J]. Acta Otolaryngol，2009,129(5):487-492. DOI：10.1080/00016480802273082.
[24]	CASANI A P, GUIDETTI G, SCHOENHUBER R, et al. Report from a Consensus Conference on the treatment of Ménières disease with betahistine：rationale，methodology and results[J]. Acta Otorhinolaryngol Ital，2018,38(5):460-467. DOI：10.14639/0392-100X-2035.
[25]	AL-TAMIMI D J, AMMOO A M, ALANI M E, et al. Pharmacokinetics and dose proportionality of betahistine in healthy individuals[J]. Sci Pharm，2020,88(1):13. DOI：10.3390/scipharm88010013.
[26]	良性阵发性位置性眩晕诊断和治疗指南（2017）[C]//中国中西医结合学会眩晕病专业委员会第二次学术大会暨河南省中西医结合学会眩晕病专业委员会第三次学术大会暨眩晕高峰论坛论文汇编，郑州，2017.
[27]	熊彬彬，赵晓明，刘劲，等. 良性阵发性位置性眩晕复位短期疗效不佳的分析[J]. 中华耳科学杂志，2016,14(4):473-477. DOI：10.3969/j.issn.1672-2922.2016.03.008.
[28]	计莉，彭新，孙勍，等. 良性阵发性位置性眩晕复位成功后残留症状特点及其影响因素[J]. 武警医学，2016,27(7):655-657. DOI：10.14010/j.cnki.wjyx.2016.07.002.
[29]	FARALLI M, LAPENNA R, GIOMMETTI G, et al. Residual dizziness after the first BPPV episode：role of otolithic function and of a delayed diagnosis[J]. Eur Arch Otorhinolaryngol，2016,273(10):3157-3165. DOI：10.1007/s00405-016-3947-z.
[30]	葛利娜，韩丽雅，黄向东，等. 倍他司汀治疗良性阵发性位置性眩晕成功手法复位后的残余头晕[J]. 浙江实用医学，2015,20(5):329-331. DOI：10.16794/j.cnki.cn33-1207/r.2015.05.006.
[31]	WU P X, LIU J P, WANG W Q, et al. Intervention strategies for residual dizziness after successful repositioning maneuvers in benign paroxysmal positional vertigo：a single center randomized controlled trial[J]. Chin J Otorhinolaryngol Head Neck Surg，2021,56(1):41-46. DOI：10.3760/cma.j.cn115330-20201109-00856.
[32]	张少华，陈瑾，陈婷，等. 手法复位联合甲磺酸倍他司汀治疗良性阵发性位置性眩晕临床研究文献的Meta分析[J]. 民航医学，2020,30(2):105-108.
[33]	吴涛，阮奕劲，石雄州，等. 盐酸倍他司汀联合手法复位治疗良性阵发性位置性眩晕的效果观察[J]. 吉林医学，2020,41(5):1122-1124.
[34]	田从哲，黄俊瑜，刘佳，等. Brandt-Daroff习服法联合倍他司汀治疗良性阵发性位置性眩晕复位后残余症状的疗效分析[J]. 中国耳鼻咽喉头颈外科，2020,27(7):410-412. DOI：10.16066/j.1672-7002.2020.07.012.
[35]	刘大为，夏菲，任媛媛. 倍他司汀联合利多卡因对良性阵发性位置性眩晕患者管石复位治疗成功后残余头晕的疗效[J]. 临床和实验医学杂志，2020,19(13):1390-1394. DOI：10.3969/j.issn.1671-4695.2020.13.014.
[36]	OH K H, SUH K D, LEE Y H, et al. Clinical utility of cervical vestibular-evoked myogenic potentials in predicting residual dizziness after benign paroxysmal positional vertigo[J]. Clin Neurophysiol，2019,130(1):95-100. DOI：10.1016/j.clinph.2018.11.005.
[37]	SEO T, SHIRAISHI K, KOBAYASHI T, et al. Residual dizziness after successful treatment of idiopathic benign paroxysmal positional vertigo originates from persistent utricular dysfunction[J]. Acta Otolaryngol，2017,137(11):1149-1152. DOI：10.1080/00016489.2017.1347824.
[38]	王立男. BPPV复位治疗后残余症状的中西医综合治疗的临床研究[D]. 沈阳：辽宁中医药大学，2019.
[39]	DE MELO NETO J S, STROPPA A E Z, PARRERA C A, et al. Reabilitação vestibular em portadores de vertigem posicional paroxística benigna[J]. Revista CEFAC，2012,15(3):510-520. DOI：10.1590/s1516-18462012005000064.
[40]	梅尼埃病诊断和治疗指南（2017）[C]//中国中西医结合学会眩晕病专业委员会第二次学术大会暨河南省中西医结合学会眩晕病专业委员会第三次学术大会暨眩晕高峰论坛论文汇编，郑州，2017.
[41]	STRUPP M, HUPERT D, FRENZEL C, et al. Long-term prophylactic treatment of attacks of vertigo in Menières disease—comparison of a high with a low dosage of betahistine in an open trial[J]. Acta Otolaryngol，2008,128(5):520-524. DOI：10.1080/00016480701724912.
[42]	LEZIUS F, ADRION C, MANSMANN U, et al. High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Menières disease：a case series[J]. Eur Arch Otorhinolaryngol，2011,268(8):1237-1240. DOI：10.1007/s00405-011-1647-2.
[43]	STRUPP M, THURTELL M J, SHAIKH A G, et al. Pharmacotherapy of vestibular and ocular motor disorders，including nystagmus[J]. J Neurol，2011,258(7):1207-1222. DOI：10.1007/s00415-011-5999-8.
[44]	ADRION C, FISCHER C S, WAGNER J, et al. Efficacy and safety of betahistine treatment in patients with Menieres disease：primary results of a long term，multicentre，double blind，randomised，placebo controlled，dose defining trial （BEMED trial）[J]. BMJ，2016,352:h6816. DOI：10.1136/bmj.h6816.
[45]	IHLER F, BERTLICH M, SHARAF K, et al. Betahistine exerts a dose-dependent effect on cochlear stria vascularis blood flow in guinea pigs in vivo[J]. PLoS One，2012,7(6):e39086. DOI：10.1371/journal.pone.0039086.
[46]	杨月嫦，庄建华，周丽丽，等. 前庭性偏头痛和梅尼埃病患者变温试验结果的比较[J]. 临床耳鼻咽喉头颈外科杂志，2016,30(1):15-18. DOI：10.13201/j.issn.1001-1781.2016.01.005.
[47]	LEE S U, KIM H J, KOO J W, et al. Comparison of caloric and head-impulse tests during the attacks of Menieres disease[J]. Laryngoscope，2017,127(3):702-708. DOI：10.1002/lary.26103.
[48]	BLÖDOW A, HEINZE M, BLOCHING M B, et al. Caloric stimulation and video-head impulse testing in Ménières disease and vestibular migraine[J]. Acta Otolaryngol，2014,134(12):1239-1244. DOI：10.3109/00016489.2014.939300.
[49]	PYYKKÖ I, EKLUND S, ISHIZAKI H, et al. Postural compensation after intratympanic gentamicin treatment of Menières disease[J]. J Vestib Res，1999,9(1):19-26.
[50]	EKVALL HANSSON E, BRATTMO M. Balance performance and self-perceived handicap among patients with Menieres disease-a comparison with healthy controls[J]. Eur J Physiother，2013,15(4):221-224. DOI：10.3109/21679169.2013.840858.
[51]	ROSSI P, FIERMONTE G, PIERELLI F. Cinnarizine in migraine prophylaxis：efficacy，tolerability and predictive factors for therapeutic responsiveness. An open-label pilot trial[J]. Funct Neurol，2003,18(3):155-159.
[52]	TOGHA M, ASHRAFIAN H, TAJIK P. Open-label trial of cinnarizine in migraine prophylaxis[J]. Headache，2006,46(3):498-502. DOI：10.1111/j.1526-4610.2006.00381.x.
[53]	BALOH R W, YUE Q, JACOBSON K M, et al. Persistent direction-changing positional nystagmus：another variant of benign positional nystagmus?[J]. Neurology，1995,45(7):1297-1301. DOI：10.1212/wnl.45.7.1297.
[54]	VON BREVERN M, ZEISE D, NEUHAUSER H, et al. Acute migrainous vertigo：clinical and oculographic findings[J]. Brain，2005,128(Pt 2):365-374. DOI：10.1093/brain/awh351.
[55]	OBERMANN M, WURTHMANN S, STEINBERG B S, et al. Central vestibular system modulation in vestibular migraine[J]. Cephalalgia，2014,34(13):1053-1061. DOI：10.1177/0333102414527650.
[56]	TOKLE G, MØRKVED S, BRÅTHEN G, et al. Efficacy of vestibular rehabilitation following acute vestibular neuritis：a randomized controlled trial[J]. Otol Neurotol，2020,41(1):78-85. DOI：10.1097/MAO.0000000000002443.
[57]	BERISAVAC I I, PAVLOVIĆ A M, TRAJKOVIĆ J J, et al. Drug treatment of vertigo in neurological disorders[J]. Neurol India，2015,63(6):933-939. DOI：10.4103/0028-3886.170097.
[58]	HAN B I, SONG H S, KIM J S. Vestibular rehabilitation therapy：review of indications，mechanisms，and key exercises[J]. J Clin Neurol，2011,7(4):184-196. DOI：10.3988/jcn.2011.7.4.184.
[59]	VAN CAUWENBERGE P B, DE MOOR S E. Physiopathology of H₃-receptors and pharmacology of betahistine[J]. Acta Otolaryngol Suppl，1997,526:43-46. DOI：10.3109/00016489709124020.
[60]	REDON C, LOPEZ C, BERNARD-DEMANZE L, et al. Betahistine treatment improves the recovery of static symptoms in patients with unilateral vestibular loss[J]. J Clin Pharmacol，2011,51(4):538-548. DOI：10.1177/0091270010369241.
[61]	SCHOLTZ A W, STEINDL R, BURCHARDI N, et al. Comparison of the therapeutic efficacy of a fixed low-dose combination of cinnarizine and dimenhydrinate with betahistine in vestibular neuritis：a randomized，double-blind，non-inferiority study[J]. Clin Drug Investig，2012,32(6):387-399. DOI：10.2165/11632410-000000000-00000.
[62]	HUGHES R J, JAMES I M, DJIANE A. The effect of betahistine methanesulphonate upon cerebral blood flow[J]. Br J Clin Pharmacol，1981,11(3):308-310. DOI：10.1111/j.1365-2125.1981.tb00541.x.
[63]	TIGHILET B, TROTTIER S, LACOUR M. Dose- and duration-dependent effects of betahistine dihydrochloride treatment on histamine turnover in the cat[J]. Eur J Pharmacol，2005,523(1/2/3):54-63. DOI：10.1016/j.ejphar.2005.09.017.
[64]	LAURIKAINEN E A, MILLER J M, QUIRK W S, et al. Betahistine-induced vascular effects in the rat cochlea[J]. Am J Otol，1993,14(1):24-30.
[65]	DELLA PEPA C, GUIDETTI G, EANDI M. Betahistine in the treatment of vertiginous syndromes：a meta-analysis[J]. Acta Otorhinolaryngol Ital，2006,26(4):208-215.
[66]	JÓZEFOWICZ-KORCZYŃSKA M, LUKOMSKI M. Electronystagmography study in patients with the insufficiency of vertebrobasilar artery after betahistine treatment[J]. Neurol Neurochir Pol，2000,34(4):645-652.
[67]	吴子明，张素珍，刘兴健，等. 甲磺酸倍他司汀治疗内耳缺血相关性眩晕的疗效研究[J]. 中国听力语言康复科学杂志，2007,5(5):26-29. DOI：10.3969/j.issn.1672-4933.2007.05.005.
[68]	KISHI T, MUKAI T, MATSUDA Y, et al. Efficacy and safety of noradrenalin reuptake inhibitor augmentation therapy for schizophrenia：a meta-analysis of double-blind randomized placebo-controlled trials[J]. J Psychiatr Res，2013,47(11):1557-1563. DOI：10.1016/j.jpsychires.2013.07.003.
[69]	JECK-THOLE S, WAGNER W. Betahistine：a retrospective synopsis of safety data[J]. Drug Saf，2006,29(11):1049-1059. DOI：10.2165/00002018-200629110-00004.
[70]	WANG Y Q, HUANG X F, FAN H Z, et al. High-dose betahistine improves cognitive function in patients with schizophrenia：a randomized double-blind placebo-controlled trial[J]. Front Psychiatry，2021,12:762656. DOI：10.3389/fpsyt.2021.762656.
[71]	WEGNER I, HALL D A, SMIT A L, et al. Betahistine for tinnitus[J]. Cochrane Database Syst Rev，2018,12(12):CD013093. DOI：10.1002/14651858.CD013093.pub2.
[72]	BUHARALIOGLU C K, ACAR S, EROL-COSKUN H, et al. Pregnancy outcomes after maternal betahistine exposure：a case series[J]. Reprod Toxicol，2018,79:79-83. DOI：10.1016/j.reprotox.2018.06.004.
[73]	BETTS T, HARRIS D, GADD E. The effects of two anti-vertigo drugs （betahistine and prochlorperazine） on driving skills[J]. Br J Clin Pharmacol，1991,32(4):455-458. DOI：10.1111/j.1365-2125.1991.tb03930.x.

推荐强度（级）	等级释义及临床建议
A	强。循证证据肯定或良好（Ⅰ~Ⅱ级）；或循证证据一般（Ⅲ~Ⅳ级），但在国内外指南中明确推荐。能够改善健康结局，利大于弊
B	中等。循证证据一般（Ⅲ~Ⅳ级）。可以改善健康结局
C	弱。循证证据不足或矛盾（Ⅴ~Ⅹ级）。无法明确利弊，但可能改善健康结局

推荐强度（级）	等级释义及临床建议
A	强。循证证据肯定或良好（Ⅰ~Ⅱ级）；或循证证据一般（Ⅲ~Ⅳ级），但在国内外指南中明确推荐。能够改善健康结局，利大于弊
B	中等。循证证据一般（Ⅲ~Ⅳ级）。可以改善健康结局
C	弱。循证证据不足或矛盾（Ⅴ~Ⅹ级）。无法明确利弊，但可能改善健康结局

证据等级（级）	分级释义
Ⅰ	基于多个随机对照试验的荟萃分析或系统评价；大样本的随机试验
Ⅱ	基于至少1个质量较高的随机对照试验；设计规范、结果明确的观察性研究或横断面研究；前瞻性队列研究
Ⅲ	基于设计良好的非随机性病例对照研究，观察性研究，非前瞻性队列研究
Ⅳ	基于非随机性回顾性研究；专家共识
Ⅴ	病例报告；基于机制的推理或基于基本原则的推理
Ⅹ	特殊情况无法进行验证但益处明显超过危害，或证据存在矛盾

证据等级（级）	分级释义
Ⅰ	基于多个随机对照试验的荟萃分析或系统评价；大样本的随机试验
Ⅱ	基于至少1个质量较高的随机对照试验；设计规范、结果明确的观察性研究或横断面研究；前瞻性队列研究
Ⅲ	基于设计良好的非随机性病例对照研究，观察性研究，非前瞻性队列研究
Ⅳ	基于非随机性回顾性研究；专家共识
Ⅴ	病例报告；基于机制的推理或基于基本原则的推理
Ⅹ	特殊情况无法进行验证但益处明显超过危害，或证据存在矛盾

指标		H₁受体	H₂受体	H₃受体	H₄受体
偶联G蛋白		Gq/11	Gs	Gi/o	Gi/o
下游信号转导通路		PLC，IP₃，DAG，Ca²⁺，PKC，AMPK，NF-κB	AC，cAMP，PKA，CREB	AC↓，cAMP↓，MAPK，Akt/GSK3	AC↓，cAMP↓，MAPK
细胞功能		突触后兴奋	突触后兴奋	突触前抑制	尚不明确
分布	相关脑区	丘脑，大脑皮质，海马，隔核，背侧丘脑，基底前脑，蓝斑，缝核，下丘脑，杏仁核，小脑，孤束核，延髓最后区	海马，基底节，杏仁核，蓝斑，缝核，黑质，丘脑，下丘脑，大脑皮质，小脑	大脑皮质，纹状体，伏隔核，基底节，下丘脑，海马，小脑	中枢非神经元
	前庭系统	半规管壶腹嵴，耳石器囊斑，内淋巴囊，前庭神经核	半规管壶腹嵴，耳石器囊斑，内淋巴囊，前庭神经核	半规管壶腹嵴，耳石器囊斑，内淋巴囊，前庭神经节，前庭神经核	耳石器囊斑，内淋巴囊，前庭神经节，前庭神经核
影响前庭功能的可能机制		（1）中枢觉醒水平；（2）前庭神经核兴奋性；（3）耳蜗微循环	前庭神经核兴奋性	（1）中枢觉醒水平；（2）中枢组胺的合成与释放；（3）前庭神经核兴奋性；（4）前庭神经兴奋性；（5）耳蜗微循环	前庭神经兴奋性